

## **Biotinylated Human PCSK9 (C-Avi)**

	Catalog#:AC13163 Derived from Human Cells
DESCRIPTION	Biotinylated Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln692(Val474Ile,Gly670Glu) is expressed with a Avi tag at the C-terminus. Accession#: Q8NBP7 Known as: Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1
FORMULATION	Supplied as a 0.2 $\mu$ m filtered solution of 50mM HEPES, 150mM NaCl, 20% Glycerol, pH 7.4.
SHIPPING	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
STORAGE	Store at $\leq$ -70°C, stable for 6 months after receipt. Store at $\leq$ -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles
QUALITY CONTROL	Mol Mass: 14&59kDa AP Mol Mass: 19&65kDa, reducing conditions. Purity: Greater than 95% as determined by reducing SDS-PAGE. Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
BACKGROUND	Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.
SDS-PAGE NK R 120 90 40 30 20 14	